Board of Directors

Gregory B. Brown, MD


Gregory B. Brown, MD was appointed to the Board in October 2016. Dr. Brown is a co-founder and Vice Chairman of HealthCare Royalty Partners (HCR Partners), a healthcare-focused private asset management firm investing in biopharmaceutical and medical products, and developing and deploying innovative, risk-mitigated investment strategies to deliver non-correlated cash flow. Dr. Brown was educated as a transplantation immunologist and trained as a thoracic and vascular surgeon. He practiced thoracic and vascular surgery in a community setting where he also founded and led an HMO. He brings particular expertise in the scientific, technical, clinical and medical evaluation of products as well as in healthcare systems and payor/reimbursement dynamics. He has been involved in sourcing, performing due diligence on and closing more than $1 billion of royalty financings.

Before co-founding HCR Partners, Dr. Brown was a partner at Paul Capital Partners, where he co-managed that firm's royalty investments as a member of the royalty management committee. Prior to beginning his principal investment career in 2003, Dr. Brown was co-head of investment banking and head of healthcare at Adams, Harkness & Hill (now Canaccord Genuity) and a ranked biotechnology research analyst at Vector Securities International. Dr. Brown holds a BA from Yale, an MD from SUNY Upstate Medical Center and an MBA from Harvard Business School. He currently serves on the boards of Aquestive Therapeutics, Inc. (NASDAQ:AQST), Cambrex Corporation (NYSE:CBM), and Faron Pharmaceuticals Oy (LSE:FARN).

Michael H. Davidson, MD


Dr. Davidson joined the Board in 2020. He was the Founder and former Chief Scientific Officer of Corvidia Therapeutics, which was recently acquired by Novo-Nordisk for $2.1 billion. Dr. Davidson also serves as Clinical Professor and Director of the Lipid Clinic at the University of Chicago Pritzker School of Medicine. He is a leading expert in the field of Lipidology and was named in The Best Doctors in America for the past 10 years. Dr. Davidson was the co-founding Chief Medical Officer of Omthera Pharmaceuticals in 2008, which was later acquired by Astra Zeneca Pharmaceutical in 2013 for $443M. He also founded the Chicago Center for Clinical Research, which became the largest investigator site in the United States and was acquired by Pharmaceutical Product Development in 1996. His research background encompasses both pharmaceutical and nutritional clinical trials including extensive research on statins, novel lipid-lowering drugs, and omega-3 fatty acids. Dr. Davidson is board-certified in internal medicine, cardiology, and clinical lipidology and served as President of the National Lipid Association from 2010 to 2011. He received his BA/MS from Northwestern University and MD from The Ohio State University School of Medicine.

Steven M. Klosk


Mr. Klosk joined the Board in 2014. He is a senior executive with extensive management experience in the life sciences industry. He is currently President, CEO and a Director at Cambrex Corporation (NYSE:CBM), one of the leading providers of active pharmaceutical ingredients, advanced intermediates and finished dosage form products to the branded and generic pharmaceutical markets. Mr. Klosk has been in his current role since May 2008 and is responsible for all aspects of Cambrex’s global business with 12 manufacturing and R&D facilities in the United States and Europe. Since 2012, Cambrex revenues have increased from $277 million to $532 million and its market capitalization has increased 4-fold.

Mr. Klosk has also held other executive positions at Cambrex Corporation, including Executive Vice President & COO; as well as President, Pharma Business Unit (2007-2008) where he had full P&L and balance sheet responsibility for four operating units in North America and Europe. Prior to this he was Executive Vice President & COO Cambrex Pharma & Biopharmaceuticals Business Unit (2003-2007) where he was responsible for managing a highly profitable global business with six operating units in North America and Europe. Earlier in his career Mr. Klosk served as Vice President, Administration for the The Genlyte Group, Inc., a publicly traded producer of lighting fixtures.

Mr. Klosk earned a BS from Cornell University and a JD from New York Law School.

David J. Mazzo, PhD

President and Chief Executive Officer

Dr. Mazzo is the President and CEO of Caladrius Biosciences, Inc., a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies for select cardiovascular and autoimmune diseases. The Company’s primary technology platform is based on the use of CD34+/CXCR4+ cells for ischemic repair in a variety of indications including critical limb ischemia, coronary microvascular disfunction and no-option refractory disabling angina (NORDA). Dr. Mazzo is a pharmaceutical executive and strategic leader with broad experience in both large and small companies gained from working in a variety of multi-cultural and multi-lingual environments in the USA, Canada, Europe and Asia. He is recognized for his exceptional strategic, scientific and regulatory expertise, upon which he has amassed a track record of >35 years of successful global product development, registration and launch. Dr. Mazzo is a demonstrated change leader uniquely adept at integrating disparate groups, turning around dysfunctional organizations and driving working groups to new levels of performance and achievement.

Dr. Mazzo is a seasoned public and private company director having served on the boards of all the companies for which he was CEO plus Essex Chimie AG (EU subsidiary of Schering-Plough), Avanir Pharmaceuticals, EyePoint Pharmaceuticals and Seneca Biopharma. For Avanir (NASDAQ: AVNR), he served from 2005 – 2015 (until the sale of Avanir to Otsuka) and was, at various times, a member of the Executive committee of the Board, Science committee, Audit committee and/or Governance committee. From 2008 to 2015, he served as chairman of the Compensation committee. For EyePoint (NASDAQ: EYPT), Dr. Mazzo has also served since 2005 and has been, at various times, a member of the Science, Audit and/or Governance committees. He has chaired the Compensation committee since 2005 and was Chairman of the Board from 2007 - 2018. For Seneca (NASDAQ: SNCA), Dr. Mazzo has served since 2019. He is a member both the Compensation and Nominating & Governance Committees.

Dr. Mazzo has spent his entire career within the pharmaceutical industry, rising quickly from the laboratory to occupy positions of increasing executive responsibility with Merck, Baxter, Rhône-Poulenc Rorer, Hoechst Marion Roussel and Schering-Plough before becoming CEO of Chugai USA (private) followed by Aeterna Zentaris (public), Regado Biosciences (which he took public) and Caladrius Biosciences (public). The diversity of his assignments has resulted in an expertise across all therapeutic areas as well as the whole of the drug development process from Discovery to Development to Product Commercialization.

Dr. Mazzo earned his Ph.D. in Analytical Chemistry as well as an M.S. in Chemistry at the University of Massachusetts (Amherst). He also holds dual degrees [B.S. in Chemistry and B.A. in Honors (Interdisciplinary Humanities)] from Villanova University. He complemented his American education as a Research Fellow at the Ecole Polytechnique Fédérale de Lausanne in Switzerland.

Steven S. Myers


Steven S. Myers joined the Board in November 2006. He currently serves as Chairperson of the Governance & Nominating Committee. He also serves on the Audit and Compensation Committees. He graduated from Stanford University with a BS in mathematics. He is a four-time serial entrepreneur, an Ernst & Young “Entrepreneur of the Year” for Software and Information Services, and a recipient of the California Governor’s Special Recognition Award for exceptional achievement in business.

Mr. Myers has served as a director of eleven public and private companies. He has conducted business in a dozen countries in Europe and Asia. His private equity investment company, Dolphin Capital Holdings, Inc. invests in companies with innovative business strategies. Portfolio investments include cyber security, biotechnology, alternative energy, distressed debt, hotels, and for income real estate.

An Obama Administration policy advisor on Cyber Security, he served in 2012 on the Department of Homeland Security Task Force on Cyber Security Resources and briefed then-DHS Secretary Napolitano on the Task Force recommendations. He was appointed to three terms on the U.S. State Department Advisory Committee on International Economic Policy, which advised the Secretary of State on foreign policy issues. At the Pacific Council on International Policy he served on the Board of Directors and as Chairman of their National Security Member Committee.

Mr. Myers founded SM&A, an Aerospace & Defense Industry management consulting firm that over 25 years grew to over $100 million in annual revenue and more than 800 employees; spearheading industry-changing innovations in competing for and managing U.S. Government contracts. During his tenure the company managed more than $360 billion in major program competitions. After conducting a successful NASDAQ listed IPO in 1998 he served as Chairman and CEO for ten years. The company was sold to private equity in 2008. An accomplished public speaker, and author, Mr. Myers is a nationally recognized thought leader on business competitiveness and is a frequent guest lecturer at the USC Marshall School of Business on entrepreneurship. He is a two-time Air Force Veteran and a highly accomplished aviator.

Cynthia Schwalm


Cynthia is currently the owner of EIR Advisory LLC, an advisory and strategic investment firm dedicated to life sciences. Prior to that, Ms. Schwalm was President and Chief Executive Officer of Ipsen North America, where she led the transformation of the company as it became the highest-growth subsidiary worldwide. Prior to joining Ipsen, she served as President of Eisai Pharmaceuticals, where she oversaw commercial operations, medical affairs and services, manufacturing, alliance management and other functions. She has also held general management roles, both domestically and internationally at Amgen Inc. and Johnson & Johnson. Ms. Schwalm began her career as an oncology/critical care nurse.

Ms. Schwalm currently serves on the boards of G1 Therapeutics Inc., Kadmon Holdings, Inc. and Hikma Pharmaceuticals. In addition, she is a steering committee member for Eshelman Institute for Innovation of the University of North Carolina. Ms. Schwalm has held positions on numerous corporate and non-profit boards, including the Women’s Leadership Advisory Board for the John F. Kennedy School of Government at Harvard University and the board of directors for the Sarah Cannon Oncology Research Institute. She currently serves as a Wharton Business School Leadership Advisor. Ms. Schwalm holds an MBA from the Wharton School of the University of Pennsylvania and a B.S.N. from the University of Delaware.

Ms. Schwalm will also serve as a member of the Audit Committee and the Science and Technology Committee of the Company.

Peter G. Traber, MD


Dr. Traber joined the Board in January 2015. He has extensive experience in medicine, science, drug development, and the pharmaceutical industry. He is currently a Partner at Alacrita Consulting, providing drug development consulting services to the biopharmaceutical industry. From 2010-2018, he was President and Chief Executive Officer, and Chief Medical Officer and since 2009 a member of the Board of Directors of Galectin Therapeutics, Inc. (NASDAQ: GALT), a publicly traded biotechnology company that is developing carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer. Since 2008, he has been President Emeritus of Baylor College of Medicine, where he was President and Chief Executive Officer from 2003 to 2008. Dr. Traber also has extensive big pharma leadership experience, serving from 2000 to 2003 as Senior Vice President of clinical development and medical affairs and Chief Medical Officer of GlaxoSmithKline. He has also served as CEO of the University of Pennsylvania Health System, and as Chair of the Department of Internal Medicine, and Chief of Gastroenterology for the University of Pennsylvania School of Medicine.

Dr. Traber has managed a cell and molecular biology research laboratory and published more than 100 research articles, reviews, and book chapters. He received his MD from Wayne State School of Medicine, a BS in chemical engineering from the University of Michigan, and a certificate in medical leadership from Wharton Business School.

Anne C. Whitaker


Anne is a seasoned healthcare executive with more than 28 years of experience across multiple companies and geographies. She has a proven track record of building and leading high-performance teams to successfully commercialize pharmaceuticals, consumer products and medical devices. Anne has been recognized in the pharmaceutical industry by Fierce Pharma as one of the top 25 Most Influential People in BioPharma in 2012 and 2013, and in 2014 as one of the top 25 Most Influential Women in BioPharma. She was recently recognized by PharmaVoice as one of the Top 100 most Inspiring Leaders in Healthcare and by Women, Inc. as one of the most Influential Corporate Directors in 2019. She is active in the North Carolina community mentoring women and men in pursuit of STEM careers and leadership positions. She is a member of Women Corporate Directors, Healthcare Businesswomen’s Association), International Women’s Forum and OnBoardNC.

Anne is the current Chairman of Aerami Therapeutics (formerly Dance Biopharm Holdings, Inc.), a private life science company reimaging the treatment of chronic diseases with their inhaled therapies. Prior to taking the Chairman role at Aerami, Anne joined as an independent Director in July of 2018 and served as the CEO from October 2018 to November 2020. She serves as an independent director on the board of Cree (CREE: NASDAQ), a LED and semiconductor company, Mallinckrodt (MKN: NYSE), a specialty pharmaceutical company, and UDG Healthcare (UDGHC: London Exchange), a pharmaceutical services company. She also serves on the Board of Trustees for the University of North Alabama, her alma mater. She has previously served on the board of Vectura, Plc (VEC-GB: London Exchange), Synta Pharmaceuticals, Inc. (SNTA: NASDAQ) now Madrigal Pharmaceuticals, Inc. (MDGL: NASDAQ), Novoclem Therapeutics, Inc., KNOW Bio, LLC, and Foundation Board for the North Carolina School of Mathematics and Science. In addition to her public company board work and private company CEO role, she is an active industry advisor to private equity and venture capital funds in the US and Europe.

Anne started her healthcare career with The Upjohn Company selling pharmaceuticals. She subsequently transitioned to GlaxoSmithKline PLC (GSK: NYSE) where she rose in the commercial ranks from a sales representative to become a Senior Vice President for the Cardiovascular, Metabolic, and Urology franchises in 2009. Anne joined Sanofi SA (SAN---FR: Euronext Paris) in 2011 as the President of the North America Region Head where she led more than 5000 commercial and medical employees to deliver ~$10B in net sales equaling > 30% of the net sales and >50% of the profit for Sanofi globally. Anne served as the CEO and President of Synta Pharmaceuticals, Inc. (SNTA: NASDAQ) in 2014 and 2015. She joined Bausch Health (BHC: NYSE) as an Executive Vice President and Company Group Chairman for the Branded Pharmaceuticals segment in mid-2015. From February 2017 until April 2018 she served as the CEO and President of Novoclem Therapeutics, Inc.

Anne holds a Bachelor of Science degree in chemistry from the University of North Alabama.